Market Overview

Insights into the Global Chronic Lower Back Pain Market (2017 to 2030) - Organize Sales and Marketing Efforts by Identifying the Best Opportunities

Share:

Dublin, April 07, 2020 (GLOBE NEWSWIRE) -- The "Chronic Lower Back Pain (CLBP) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the Chronic lower back pain (CLBP), historical and forecasted epidemiology as well as the Chronic lower back pain (CLBP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Chronic lower back pain (CLBP) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Chronic lower back pain (CLBP) market size from 2017 to 2030. The Report also covers current Chronic lower back pain (CLBP) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Chronic low back pain (CLBP) is defined as pain that persists for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain. Low back pain is very common and at one point everyone must have faced this problem. Lower back pain that is long-term (for more than 3 months) is called chronic low back pain, this condition might originate from an injury, disease, or stress on different structures of the body, and pain may vary significantly and maybe felt as bone pain, nerve pain, or muscle pain.

The intensity of the pain also ranges from mild to severe. CLBP is the second leading cause of disability worldwide being major welfare and economic problem. The prevalence of CLBP in adults has increased significantly in the last decade and is continuously increasing vividly in the aging population. This condition affects men and women in all ethnic groups equally. This disease also leads to stress, depression, and anxiety. CLBP affects physically and psychologically and creates a significant amount of economic burden due to loss of function, loss of work productivity, treatment costs, and disability payments.

The probable causes of CLBP are the curve of the spine, such as scoliosis or kyphosis, medical problems (fibromyalgia or rheumatoid arthritis), and piriformis syndrome (a pain disorder involving a muscle in the buttocks called the piriformis muscle). Many people with CLBP have arthritis or tear of the spine due to heavy exercise, herniated disk, or due to surgery. A herniated disc is the part of the spinal disk pushed onto the nearby nerve. Usually, these disks provide space and cushion in the spine and the loss of movement can be seen as overtime if these disks dry out and become thinner and brittle. Spinal Stenosis is the condition that arises if the spaces between the spinal nerves and spinal cord become more narrowed.

Scope of the Report

  • The report covers the descriptive overview of Chronic low back pain (CLBP), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Chronic low back pain (CLBP) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Chronic low back pain (CLBP) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Chronic low back pain (CLBP) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Chronic low back pain (CLBP) market.

Report Highlights

  • In the coming years, Chronic low back pain (CLBP) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic low back pain (CLBP) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Chronic low back pain (CLBP). Launch of emerging therapies will significantly impact the Chronic low back pain (CLBP) market.
  • The in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Topics Covered:

1 Key Insights

2 Chronic Lower Back Pain (CLBP) Market Overview at a Glance
2.1 Market (%) Distribution of CLBP in 2017
2.2 Market (%) Distribution of CLBP in 2030

3 Executive Summary

4 SWOT Analysis

5 Chronic Lower Back Pain (CLBP): Disease Background and Overview
5.1 Introduction
5.2 Signs and Symptoms
5.3 Causes and Risk Factors
5.4 Genetics of Chronic Lower Back Pain
5.5 Pathophysiology
5.5.1 Degenerative Cascade
5.5.2 Mechanistic factors involved behind the cause of CLBP
5.5.3 Neuroplasticity and central sensitization
5.5.4 Connective tissue remodeling in CLBP
5.5.5 Effect of connective tissue pathology on sensory afferent modulation
5.5.6 CLBP and Connective Tissue Remodeling
5.5.7 Pathophysiological model
5.6 Type of pain
5.6.1 Diskogenic pain
5.6.2 Lumbar spinal stenosis
5.6.3 Sacroiliac pain
5.6.4 Facet-joint pain
5.6.5 Radicular pain
5.6.6 Muscular pain
5.7 Diagnosis
5.7.1 Clinical History
5.7.2 Physical Examination
5.7.3 Imaging Guidelines
5.7.4 Assessment of Pain

6 Epidemiology Methodology

7 Epidemiology and Patient Population
7.1. Key Findings
7.2. Total Prevalent Population of Chronic Lower Back Pain in the 7MM
7.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the 7MM
7.4. Gender- Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM
7.5. Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM
7.6. Severity Specific Diagnosed Prevalence of Chronic Lower Back Pain in the 7MM

8 United States Epidemiology

9 EU5 Epidemiology

10 Japan Epidemiology


11 Treatment Algorithm, Current Treatment, and Medical Practices
11.1. Non-pharmacological treatments
11.2. Pharmacologic Treatments
11.2.1. Non-opioids Analgesics
11.2.2. Opioid Analgesics
11.2.3. Tramadol W
11.2.4. Antidepressants
11.2.5. Muscle relaxants
11.3. Treatment Algorithm

12 Proposed Guidelines for Chronic Lower Back Pain
12.1. NICE Guidelines
12.1.1. Recommendation
12.2. Center of disease control and prevention (CDC) Guidelines
12.2.1. Recommendations
12.3. American College of Physicians (ACP) Guidelines
12.3.1. Recommendations:

13 Unmet Needs

14 Marketed Products
14.1. Cymbalta (Duloxetine): Eli Lilly and Company
14.2. Xtampza: Collegium Pharmaceutical
14.3. Butrans (buprenorphine): Purdue Pharma
14.4. Belbuca: BioDelivery Sciences International

15 Emerging Therapies
15.1. Key Cross Competition
15.2. NKTR-181: Nektar Therapeutics
15.3. Tanezumab: Eli Lilly/Pfizer
15.4. Fasinumab: Regeneron Pharmaceuticals/ Teva Pharmaceuticals
15.5. MPC-06-ID (Rexlemestrocel-L): Mesoblast
15.6. CAM2038: Braeburn Pharmaceuticals/Camurus
15.7. Egalet-002: Egalet Corporation
15.8. ALLOD-2: Allodynic Therapeutics
15.9. Clonidine Micropellets (STX-051): Sollis Therapeutics
15.10. GRT6005: Grnenthal GmbH
15.11. AB001: Frontier Biotechnologies
15.12. ASP7962: Astellas Pharma Europe B.V.
15.13. AXS-02 (disodium zoledronate tetrahydrate): Axsome Therapeutics
15.14. YH14618: Yuhan Corporation
15.15. IDCT: DiscGenics
15.16. SP-102: Semnur Pharmaceuticals
15.17. SX600: SpineThera

16 Market Forecast Methodology

17 Chronic Lower Back Pain (CLBP): 7MM Market Analysis
17.1. Key Findings
17.2. Market Size of Chronic Lower Back Pain in 7MM
17.3. Market Size of Chronic Lower Back Pain by Therapies in the 7MM
17.4. Opioid Epidemic across the 7MM Countries

18 Conjoint Analysis

19 United States: Market Outlook

20 EU-5 countries: Market Outlook

21 Japan Market Outlook

22 Case Reports

Companies Mentioned

  • Eli Lilly and Company
  • Collegium Pharmaceutical
  • Purdue Pharma
  • BioDelivery Sciences International
  • Eli Lilly/Pfizer
  • Regeneron Pharmaceuticals/ Teva Pharmaceuticals
  • Mesoblast

For more information about this report visit https://www.researchandmarkets.com/r/2bmqr3

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

Primary Logo

View Comments and Join the Discussion!
 

Latest Ratings

StockFirmActionPT
WORKPiper SandlerMaintains40.0
TDOCPiper SandlerMaintains220.0
SPWHPiper SandlerMaintains15.0
NTBPiper SandlerMaintains30.0
MDBPiper SandlerMaintains226.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com